Platinum and ruthenium complexes as promising molecules in cancer therapy

• Main Authors: Avramović Nataša, Ignjatović Nikola, Savić Aleksandar
• Format: Article
• Language: English
• Published: Serbian Medical Society 2019-01-01
• Series: Srpski Arhiv za Celokupno Lekarstvo
• Subjects: cancer therapy; platinum; ruthenium; metal complexes; anticancer activity
• Online Access: http://www.doiserbia.nb.rs/img/doi/0370-8179/2019/0370-81791800075A.pdf

Cancer is one of the most common fatal diseases in humans nowadays. About 20 million new cancer cases are expected in the next two decades worldwide. The development of new chemotherapeutic agents with improved properties is presently the main challenge in the medicinal chemistry. Cisplatin was introduced to oncology in 1978 as first chemotherapeutic agent regarding its specific interaction with DNA, leading to its damage and causing the cell death. Since the first application of cisplatin in cancer therapy, there has been a growing interest in new metal-based compounds, in particular platinum and ruthenium complexes, with better anticancer activity and less side-effects compared to cisplatin. Carboplatin and oxaliplatin have shown promising action against some types of cancer, which are resistant to cisplatin. With the aim to overcome cross-resistance to these Pt(II) drugs, bioavailable platinum complexes (satraplatin and picoplatin) firstly found application as orally administered drugs, as well as some combined therapies of Pt(II) drugs (cisplatin, picoplatin) with specific resistant modulators. In recent years, novel polymer and liposomal formulations of platinum drugs (prolindac, lipoplatin, lipoxal, aroplatin) have been designed with strategy to improve drug delivery to target cancer cells and reduce toxicity. Complexes based on ruthenium have great potential to become leading candidates for the medical use in anticancer therapy. Some of these compounds have shown good anticancer activity, both in vitro and in vivo and two of them (KP1019 and NAMI-A) have passed clinical trials and given promising results. [Projects of the Serbian Ministry of Education, Science and Technological Development, Grant no. 172023, Grant no. III 46010, and Grant no. 172035]